173 countries adopt AMR plans, but testing and treatment gaps persist – WHO – Businessday NG

The World Health Organisation (WHO) says 173 countries have developed national plans to tackle Antimicrobial Resistance (AMR), but inadequate funding, testing and treatment continue to expose patients to drug-resistant infections worldwide.

WHO disclosed this in a statement on Monday, saying it was its latest Tracking Antimicrobial Resistance Country Self-assessment Survey (TrACSS), released ahead of World AMR Awareness Week.

“The 2026 survey, completed by 183 countries representing 94 per cent of WHO Member States, showed that countries with AMR plans more than doubled from 79 in 2017.

“However, only 22 per cent of countries reported having the necessary funding and fully implementing their national AMR action plans, leaving significant gaps in patient protection.

“Approximately one in six laboratory-confirmed bacterial infections worldwide was resistant to antibiotics in 2023, making common infections increasingly difficult to treat,” it said.

The organisation warned that AMR makes routine medical procedures, including surgery, childbirth and cancer treatment, riskier because medicines increasingly lose their effectiveness against resistant microorganisms.

WHO Director-General, Dr Tedros Ghebreyesus, said that national plans were essential to protecting medicines, but stressed that countries must translate commitments into action through adequate investments.

Ghebreyesus called for increased investment in infection prevention, surveillance, equitable access to essential antimicrobials and quality diagnostics to ensure patients receive appropriate treatment when necessary.

On diagnostic capacity, he reported that only 36 per cent of countries had national reference laboratories equipped to test selected bacteria and fungi.

“The figure falls short of the global target of ensuring 80 per cent of countries have comprehensive bacterial and fungal resistance testing capacity by 2030.

“Inadequate diagnostic testing could result in patients receiving ineffective or unnecessary antibiotics, while resistant infections and outbreaks might remain undetected,” Ghebreyesus said.

“The survey also showed that only 63 per cent of countries had guidelines for appropriate antimicrobial use, while slightly more than half had surveillance systems monitoring antibiotic consumption and resistance levels.

“To address the gaps, WHO introduced two practical tools under its AMR Diagnostic Initiative, providing a prioritised catalogue of diagnostic tests and guidance for clinical laboratories.

“The tools are designed to strengthen laboratories’ capacity to diagnose bacterial and fungal infections, supporting timely detection and appropriate treatment of drug-resistant diseases,” he said.

According to him, the World AMR Awareness Week, scheduled for Nov. 18 to Nov. 24, is a global campaign aimed at raising awareness and accelerating efforts to prevent the emergence and spread of drug-resistant infections.

“The 2026 campaign, themed “One Health, one action: Prevent AMR now”, highlights the interconnected health of humans, animals, plants and the environment,” he said.

Ghebreyesus called on governments, farmers, veterinarians, environmental experts and communities to strengthen collective efforts towards preventing antimicrobial resistance.

Advertisement

Source:

Businessday NG